Dyax Corp. (DYAX) HAE Drug Meets Main Goal; Shares Jump
8/15/2008
Aug 18 (Reuters) - Biopharmaceutical company Dyax Corp said its product candidate for the treatment of hereditary angioedema (HAE) met the main goal of a late-stage clinical trial, sending its shares up 26 percent.